Lymphangiogenesis: a new paradigm for cancer progression and therapy

Published: June 3, 2009
Abstract Views: 126
PDF: 149
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Angiogenesis and permeability of blood vessels are regulated by vascular endothelial growth factor (VEGF) via its two receptors VEGFR-1 and VEGFR-2. The VEGFR-3 receptor does not bind VEGF and its expression becomes restricted mainly to lymphatic endothelia during development. We have found that homozygous VEGFR-3 targeted mice die around midgestation due to failure of cardiovascular development. We have also purified and cloned the VEGFR-3 ligand, VEGF-C. Transgenic mice expressing VEGF-C show evidence of lymphangiogenesis and VEGF-C knockout mice have defective lymphatic vessels. The proteolytically processed form of VEGF-C binds also to VEGFR-2 and is angiogenic.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Alitalo, K. (2009). Lymphangiogenesis: a new paradigm for cancer progression and therapy. Hematology Meeting Reports (formerly Haematologica Reports), 1(9). https://doi.org/10.4081/hmr.v1i9.326